On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study
M. Castro (Kansas City, United States), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), S. Roseti (Gaithersburg, United States), K. Kmita (Warsaw, Poland), B. Cook (Gaithersburg, United States), N. Martin (Leicester, United Kingdom), J. Llanos-Ackert (California, United States), A. Menzies-Gow (London, United Kingdom)
Source: International Congress 2022 – Recent advances in biological treatments for asthma
Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3676
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Castro (Kansas City, United States), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), S. Roseti (Gaithersburg, United States), K. Kmita (Warsaw, Poland), B. Cook (Gaithersburg, United States), N. Martin (Leicester, United Kingdom), J. Llanos-Ackert (California, United States), A. Menzies-Gow (London, United Kingdom). On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study. 3676
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|